Accelerated Approval Granted to a Novel Drug Combination That Treats Patients with a Common Type of Non-Hodgkin Lymphoma

  Each year over eighteen thousand people in the United States are diagnosed with diffuse large B-cell lymphoma (DLBCL) a common type of non-Hodgkin lymphoma. A recent FDA news release…

Continue Reading Accelerated Approval Granted to a Novel Drug Combination That Treats Patients with a Common Type of Non-Hodgkin Lymphoma
Utility of Allogeneic Stem Cell Transplant in Non-Hodgkin Lymphoma Unclear, Report Says
sasint / Pixabay

Utility of Allogeneic Stem Cell Transplant in Non-Hodgkin Lymphoma Unclear, Report Says

According to a story from Science Daily, a review of studies focused on allogeneic stem cell transplants as a treatment for non-Hodgkin lymphoma found that it wasn't possible to conclude…

Continue Reading Utility of Allogeneic Stem Cell Transplant in Non-Hodgkin Lymphoma Unclear, Report Says

A Look at Progress in Healthcare and a Glimpse into the Future

  The Asco Post recently interviewed Dr. Jean Pierre Bizzari, the Executive Vice President of Celgene, a multinational bioparmaceutical company. The interview covered various aspects of research and development (R&D)…

Continue Reading A Look at Progress in Healthcare and a Glimpse into the Future
Possible Treatment for Marginal Zone Lymphoma Earns Orphan Drug Designation
GDJ / Pixabay

Possible Treatment for Marginal Zone Lymphoma Earns Orphan Drug Designation

According to a story from globenewswire.com, the biopharmaceutical company TG Therapeutics, Inc. recently made an announcement declaring that the US Food and Drug Administration (FDA) had awarded the company Orphan…

Continue Reading Possible Treatment for Marginal Zone Lymphoma Earns Orphan Drug Designation

Preliminary Data from Phase 1 Trial for Multiple Myeloma Indicates Complete Response in a Patient

Phase 1 Trial A Phase 1 trial by Gamida Cell is examining a new potential treatment option for patients with multiple myeloma and relapsed/refractory non-Hodgkin's lymphoma who have not responded…

Continue Reading Preliminary Data from Phase 1 Trial for Multiple Myeloma Indicates Complete Response in a Patient
67 Year Old Non-Hodgkin’s Lymphoma Patient Given Second Chance at Life After Experimental Cell Therapy
source: pixabay.com

67 Year Old Non-Hodgkin’s Lymphoma Patient Given Second Chance at Life After Experimental Cell Therapy

  A grandmother of four in Maryland has recently become the first cancer patient to complete the experimental CAR-T cell procedure at Georgetown University Hospital. Daisy Diggs 67, who was…

Continue Reading 67 Year Old Non-Hodgkin’s Lymphoma Patient Given Second Chance at Life After Experimental Cell Therapy

A Recap on 2018: Record Number of Drugs Approved by the FDA for Rare Diseases

Each year the Food and Drug Administration approves dozens of new therapies to fulfill unmet needs for various patient populations. It's just been published that in 2018 they approved a…

Continue Reading A Recap on 2018: Record Number of Drugs Approved by the FDA for Rare Diseases
Rare Blood Cancer Trial Data to be Presented in Upcoming Conference
allinonemovie / Pixabay

Rare Blood Cancer Trial Data to be Presented in Upcoming Conference

According to a story from investors.amgen.com, the drug developer Amgen recently announced its intent to present all new clinical trial data which will feature its latest work in testing a…

Continue Reading Rare Blood Cancer Trial Data to be Presented in Upcoming Conference